Ultra Low Dose Radiation Therapy for Treating Skin Lesions in Mycosis Fungoides Patients Phase 2 Study Evaluating Local Disease Control and Symptom Relief

What this Trial Is About

Researchers are evaluating ultra low dose radiation therapy as a treatment for patients with mycosis fungoides, a type of cutaneous lymphoma. This phase II trial aims to see how well this lower dose radiation controls skin lesions compared to higher doses and whether it reduces side effects. The study includes patients with all stages of the disease and explores effects on tumor control, symptom relief, survival, and skin toxicity. Participants receive ultra low dose radiation therapy at the physicians discretion targeting lesions that are 1 cm or smaller in height on the skin. Multiple lesions per patient can be treated individually. The study also includes assessments of the skin microbiome before and after radiation. Treatments are given locally, focusing on controlling each lesion. During the study, patients are followed at 4-6 weeks and 10-14 weeks after treatment, then every 3 months for 6-8 months, and finally every 6-12 months for up to 2 years. Researchers measure local lesion control at 12 weeks, along with response rates, symptom relief, skin toxicity, overall and progression-free survival, quality of life, and changes in skin microbiome. Questionnaires and quality of life assessments are also part of the study.

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides